Suvi Hartikainen, Ville Vepsäläinen, Tuomo Tompuri, Tiina M Laitinen, Marja Hedman, Tomi Laitinen
{"title":"心脏代谢紊乱影响心肌[18F]氟脱氧葡萄糖摄取-对诊断性PET/CT成像的影响。","authors":"Suvi Hartikainen, Ville Vepsäläinen, Tuomo Tompuri, Tiina M Laitinen, Marja Hedman, Tomi Laitinen","doi":"10.1186/s13550-025-01278-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Corresponding to impaired insulin response in skeletal muscle, insulin resistance may occur in the myocardium, suggesting a link between cardiometabolic disorders and cardiac glucose metabolism. We aimed to investigate whether cardiometabolic disorders predict myocardial [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) uptake suppression in cardiac positron emission tomography / computed tomography (PET/CT) following a ketogenic diet and fasting.</p><p><strong>Results: </strong>The study included 100 patients undergoing [<sup>18</sup>F]FDG-PET/CT following a ketogenic diet of 1-2 days and a 12 h fast. Blood glucose, insulin, β-hydroxybutyrate (BHB), cholesterol, triglycerides and free fatty acid (FFA) levels were measured before [<sup>18</sup>F]FDG injection and later off-diet following overnight fast. The homeostatic model assessment-insulin resistance (HOMA-IR) value was calculated. Non-contrast computed tomography was used to assess the presence of fatty liver and visceral and subcutaneous fat areas. Suppression of myocardial [<sup>18</sup>F]FDG uptake was considered adequate if myocardial uptake was equal to or lower than the blood pool background. Compared to inadequate suppression, adequate suppression was associated with higher levels of BHB (median 0.26 mmol/l for inadequate and 0.43 mmol/l for adequate suppression, p = 0.004), FFA (0.58 mmol/l and 0.76 mmol/l respectively, p < 0.001), triglycerides (0.87 mmol/l and 1.12 mmol/l respectively, p = 0.028), and lower liver-spleen attenuation ratios (1.17 and 1.04 respectively, p = 0.013). Low HDL cholesterol, high triglycerides and off-diet HOMA-IR, as well as visceral adiposity, fatty liver and hypertension, predicted adequate suppression in men. Elevated BHB and FFA were significant predictors of adequate suppression in women.</p><p><strong>Conclusions: </strong>Cardiometabolic disorders are associated with lower myocardial [<sup>18</sup>F]FDG uptake. Insulin resistance and several other cardiometabolic risk factors are associated with attenuated uptake, especially in men. In women, factors reflecting metabolic response to a ketogenic diet and fasting have a more pronounced effect on myocardial [<sup>18</sup>F]FDG uptake.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"80"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214106/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cardiometabolic disorders affect myocardial [<sup>18</sup>F]fluorodeoxyglucose uptake- impact on diagnostic PET/CT imaging.\",\"authors\":\"Suvi Hartikainen, Ville Vepsäläinen, Tuomo Tompuri, Tiina M Laitinen, Marja Hedman, Tomi Laitinen\",\"doi\":\"10.1186/s13550-025-01278-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Corresponding to impaired insulin response in skeletal muscle, insulin resistance may occur in the myocardium, suggesting a link between cardiometabolic disorders and cardiac glucose metabolism. We aimed to investigate whether cardiometabolic disorders predict myocardial [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) uptake suppression in cardiac positron emission tomography / computed tomography (PET/CT) following a ketogenic diet and fasting.</p><p><strong>Results: </strong>The study included 100 patients undergoing [<sup>18</sup>F]FDG-PET/CT following a ketogenic diet of 1-2 days and a 12 h fast. Blood glucose, insulin, β-hydroxybutyrate (BHB), cholesterol, triglycerides and free fatty acid (FFA) levels were measured before [<sup>18</sup>F]FDG injection and later off-diet following overnight fast. The homeostatic model assessment-insulin resistance (HOMA-IR) value was calculated. Non-contrast computed tomography was used to assess the presence of fatty liver and visceral and subcutaneous fat areas. Suppression of myocardial [<sup>18</sup>F]FDG uptake was considered adequate if myocardial uptake was equal to or lower than the blood pool background. Compared to inadequate suppression, adequate suppression was associated with higher levels of BHB (median 0.26 mmol/l for inadequate and 0.43 mmol/l for adequate suppression, p = 0.004), FFA (0.58 mmol/l and 0.76 mmol/l respectively, p < 0.001), triglycerides (0.87 mmol/l and 1.12 mmol/l respectively, p = 0.028), and lower liver-spleen attenuation ratios (1.17 and 1.04 respectively, p = 0.013). Low HDL cholesterol, high triglycerides and off-diet HOMA-IR, as well as visceral adiposity, fatty liver and hypertension, predicted adequate suppression in men. Elevated BHB and FFA were significant predictors of adequate suppression in women.</p><p><strong>Conclusions: </strong>Cardiometabolic disorders are associated with lower myocardial [<sup>18</sup>F]FDG uptake. Insulin resistance and several other cardiometabolic risk factors are associated with attenuated uptake, especially in men. In women, factors reflecting metabolic response to a ketogenic diet and fasting have a more pronounced effect on myocardial [<sup>18</sup>F]FDG uptake.</p>\",\"PeriodicalId\":11611,\"journal\":{\"name\":\"EJNMMI Research\",\"volume\":\"15 1\",\"pages\":\"80\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214106/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13550-025-01278-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01278-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
背景:与骨骼肌胰岛素反应受损相对应,胰岛素抵抗可能发生在心肌中,这表明心脏代谢障碍与心脏糖代谢之间存在联系。我们的目的是研究在生酮饮食和禁食后,心脏正电子发射断层扫描/计算机断层扫描(PET/CT)中,心脏代谢疾病是否能预测心肌氟脱氧葡萄糖(FDG)摄取抑制[18F]。结果:该研究纳入了100例在生酮饮食1-2天和禁食12小时后接受FDG-PET/CT [18F]的患者。[18F]注射FDG前及禁食过夜后断食后测定血糖、胰岛素、β-羟基丁酸(BHB)、胆固醇、甘油三酯和游离脂肪酸(FFA)水平。计算稳态模型评估-胰岛素抵抗(HOMA-IR)值。使用非对比计算机断层扫描来评估脂肪肝、内脏和皮下脂肪区域的存在。如果心肌摄取等于或低于血池背景,则认为对FDG摄取的抑制[18F]是充分的。与不充分抑制相比,充分抑制与BHB(不充分抑制的中位数为0.26 mmol/l,充分抑制的中位数为0.43 mmol/l, p = 0.004)和FFA(分别为0.58 mmol/l和0.76 mmol/l, p)水平升高相关。结论:心脏代谢紊乱与心肌[18F]FDG摄取降低相关。胰岛素抵抗和其他几个心脏代谢危险因素与摄取减少有关,尤其是在男性中。在女性中,反映生酮饮食和禁食代谢反应的因素对心肌FDG摄取的影响更为明显[18F]。
Background: Corresponding to impaired insulin response in skeletal muscle, insulin resistance may occur in the myocardium, suggesting a link between cardiometabolic disorders and cardiac glucose metabolism. We aimed to investigate whether cardiometabolic disorders predict myocardial [18F]fluorodeoxyglucose ([18F]FDG) uptake suppression in cardiac positron emission tomography / computed tomography (PET/CT) following a ketogenic diet and fasting.
Results: The study included 100 patients undergoing [18F]FDG-PET/CT following a ketogenic diet of 1-2 days and a 12 h fast. Blood glucose, insulin, β-hydroxybutyrate (BHB), cholesterol, triglycerides and free fatty acid (FFA) levels were measured before [18F]FDG injection and later off-diet following overnight fast. The homeostatic model assessment-insulin resistance (HOMA-IR) value was calculated. Non-contrast computed tomography was used to assess the presence of fatty liver and visceral and subcutaneous fat areas. Suppression of myocardial [18F]FDG uptake was considered adequate if myocardial uptake was equal to or lower than the blood pool background. Compared to inadequate suppression, adequate suppression was associated with higher levels of BHB (median 0.26 mmol/l for inadequate and 0.43 mmol/l for adequate suppression, p = 0.004), FFA (0.58 mmol/l and 0.76 mmol/l respectively, p < 0.001), triglycerides (0.87 mmol/l and 1.12 mmol/l respectively, p = 0.028), and lower liver-spleen attenuation ratios (1.17 and 1.04 respectively, p = 0.013). Low HDL cholesterol, high triglycerides and off-diet HOMA-IR, as well as visceral adiposity, fatty liver and hypertension, predicted adequate suppression in men. Elevated BHB and FFA were significant predictors of adequate suppression in women.
Conclusions: Cardiometabolic disorders are associated with lower myocardial [18F]FDG uptake. Insulin resistance and several other cardiometabolic risk factors are associated with attenuated uptake, especially in men. In women, factors reflecting metabolic response to a ketogenic diet and fasting have a more pronounced effect on myocardial [18F]FDG uptake.
EJNMMI ResearchRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍:
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.